Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) will hold its annual
general meeting of shareholders (“AGM”) at 10:30 a.m. CEST
on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009
Marseille.
The Notice of Meeting of this AGM was published on April 16,
2025 in the French legal bulletin. It includes the agenda, the
proposed resolutions as well as instructions to participate and
vote in this AGM.
Documents and information relating to this meeting will be made
available to shareholders in accordance with current regulations,
and will also be available in the Investors section of the
Company's website.
****
The annual general meeting will also be
broadcasted live and available at the following link:
Innate Pharma 2025 annual general meeting
A guided tour of the Company's laboratories is
organized on the same day at 9:15 a.m. CEST for shareholders.
Shareholders can register for the tour at this link: company
laboratories tour registration form.
****
Precision regarding the AGM:
Only shareholders having registered their shares at least two
business days prior to the date of the AGM, by zero hour Paris
time, will be able to participate.
Shareholders holding “au porteur” (bearer) shares will need to
obtain an “attestation de participation” (certificate of
shareholding) from their brokers. This “attestation de
participation” must be attached to the voting or proxy form.
Written questions from shareholders must be received four
business days prior to the AGM at the latest (by e-mail to
investors@innate-pharma.fr).
Shareholders can also obtain the documents and information in
preparation of the AGM (as described in article R. 225-83 of the
French Code de Commerce) by sending a request by e-mail to
investors@innate-pharma.fr.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through three therapeutic approaches: multi-specific NK Cell
Engagers via its ANKET® (Antibody-based NK cell Engager
Therapeutics) proprietary platform and Antibody Drug Conjugates
(ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to
address multiple tumor types as well as IPH4502, a differentiated
ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb
lacutamab is developed in advanced form of cutaneous T cell
lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb
monalizumab is developed with AstraZeneca in non-small cell lung
cancer.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com. Follow
us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2023, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public by
the Company. References to the Company’s website and the AMF
website are included for information only and the content contained
therein, or that can be accessed through them, are not incorporated
by reference into, and do not constitute a part of, this press
release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250415963401/en/
For additional information, please contact:
Investors Innate Pharma
Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Gráfico Histórico do Ativo
De Abr 2025 até Mai 2025
Innate Pharma (NASDAQ:IPHA)
Gráfico Histórico do Ativo
De Mai 2024 até Mai 2025
